Fernanda Amary, M <br/><br/>
Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy.  [electronic resource] 

 -  Cancer medicine  Aug 2014 
 - 980-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2045-7634 
<br/><br/><label>Standard No.: </label>10.1002/cam4.268  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Bone Neoplasms--drug therapy<br/>Chemotherapy, Adjuvant<br/>Drug Resistance, Neoplasm--genetics<br/>Female<br/>Gene Amplification<br/>Humans<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Neoadjuvant Therapy<br/>Osteosarcoma--drug therapy<br/>Receptor, Fibroblast Growth Factor, Type 1--genetics<br/>Retrospective Studies<br/>Treatment Outcome<br/>Young Adult